12:21 PM EDT, 03/12/2025 (MT Newswires) -- Merck ( MRK ) said Wednesday that the investigational two-drug regimen of doravirine/islatravir maintained HIV-1 viral suppression at week 48 in two phase 3 trials.

The regimen met the primary success measure for non-inferiority to comparator antiretroviral therapies in both trials. One involved adults with HIV-1 infection virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide, and the other included those on broader baseline antiretroviral therapy, Merck ( MRK ) said.

The safety profile of the regimen was generally comparable to the comparator regimens, with no treatment-emergent resistance to doravirine or islatravir observed in either trial, the company said.

Merck ( MRK ) said it plans to begin seeking marketing authorization from regulators by mid-2025.

Price: 94.25, Change: -0.48, Percent Change: -0.51